By: Da Hee Han, PharmD From: empr.com Celltrion and Teva announced that the Food and Drug Administration (FDA) has approved Herzuma (trastuzumab-pkrb) injection, a new biosimilar to Herceptin (trastuzumab; Genentech) for certain HER2-overexpressing breast cancer indications. Patients should be selected for treatment based on an FDA-approved companion diagnostic for a trastuzumab product. Specifically, Herzuma is approved to treat: Adjuvant breast …
Trials Answer Questions About Duration of Treatment in HER2+ Breast Cancer
By: Angelica Welch From: oncnursingnews.com The optimal duration of treatment for patients with HER2-positive breast cancer has been called into question by recent findings from the NSABP B-52, PERSEPHONE, and APT clinical trials. Priya Rastogi, MD, senior associate medical director, NSABP Medical Affairs, associate professor of Medicine, University of Pittsburgh, shed light on the subject during a presentation she gave …
Study reveals new treatment option for women with advanced breast cancer resistant to hormone therapy
Source: esmo.org From: news-medical.net Treatment with the cyclin dependent kinase (CDK) 4/6 inhibitor palbociclib achieves a clinically meaningful improvement in overall survival in patients with hormone receptor positive (HR+) human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer that has relapsed or progressed on hormonal therapy, according to the final analysis of overall survival results from the PALOMA-3 study …
Announcement: HER2+ Breast Cancer Program on Lifetime Channel Wednesday Oct 24th at 7:30 am ET/PT
On behalf of Puma Biotechnology, I wanted to let you know of a program by Access Health on HER2+ Breast Cancer, airing on the Lifetime channel. Puma was honored to sponsor this program which features Dr. Reshma Mahtani, Associate Professor, Silvestre Comprehensive Cancer Center, University of Miami. In this program and during the interview, Dr. Mahtani will address the following …
WVU researchers working to stop cancer-growth protein
Courtesy of: WVU Today From: williamsondailynews.com What do one in five breast cancers have in common? Large amounts of a protein called HER2 (or human epidermal growth factor receptor 2). “Every healthy cell produces a normal amount of HER2, but HER2 is produced 10 to 20 times more in a cancer cell,” said Yehenew Agazie, an associate professor of biochemistry …
Older Breast Cancer Patients Require Special Consideration
By: Elizabeth Gardner From: onclive.com Treating older patients with HER2-positive or triple-negative breast cancer (TNBC) must include more quality of life considerations and different types of survival calculations, even when the basic tools and treatment regimens are similar to those used in younger patients, according to a talk at the 2017 Lynn Sage Breast Cancer Symposium. “The real question isn’t …
Taselisib Added to Letrozole Boosts Response in Breast Cancer
By: Alexander M. Castellino, PhD From: medscape.com A new investigational PI3KCA targeted agent, taselisib (Genentech/Roche), has shown benefit in postmenopausal women with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) early-stage breast cancer. Adding the new agent to letrozole significantly improved response rates compared with letrozole alone in all patients, but the improvement was more robust for patients with …
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s DS-8201 for HER2-Positive Metastatic Breast Cancer
From: PR Newswire — Breakthrough Therapy designation received for the treatment of patients with HER2-positive, locally advanced or metastatic breast cancer who have been treated with trastuzumab and pertuzumab and have disease progression after ado-trastuzumab emtansine (T-DM1) — HER2-positive metastatic breast cancer often advances to the point where no currently approved HER2-targeted treatments continue to control the disease — Designation …
New compound boosts treatment for aggressive breast cancer
By: Ana Sandoiu From: medicalnewstoday.com Although breast cancer survival rates are overall very high, some forms of cancer are more difficult to treat than others. However, a new compound proves highly effective against these types by targeting a protein that makes cancer cells resistant to treatment. Triple-negative breast cancer is often resistant to treatment. Its name refers to the hormone …
Novartis receives FDA approval for first-of-its-kind Kisqali® Femara® Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer
From: PR Newswire — Physicians now have the option of prescribing Kisqali and Femara together in one convenient co-pack — Co-Pack allows patients ability to obtain Kisqali and Femara with a single co-pay — Approval comes less than two months after Kisqali received US FDA approval Novartis announced today that the US Food and Drug Administration (FDA) has approved the …
- Page 1 of 2
- 1
- 2